N-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide

• ChemBase编号: 89
• 分子式: C19H27N3O5S2
• 平均质量: 441.56478
• 单一同位素质量: 441.13921298
• SMILES: S(=O)(=O)(Nc1ccc(CCN(CCOc2ccc(NS(=O)(=O)C)cc2)C)cc1)C
• Canonical SMILES: CN(CCc1ccc(cc1)NS(=O)(=O)C)CCOc1ccc(cc1)NS(=O)(=O)C
• InChI: InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3
• InChIKey: IXTMWRCNAAVVAI-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: N-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide
• IUPAC传统名: N-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide
• 商标名: Dofetilida; Tikosyn
• 别名: Dofetilida [INN-Spanish]; Dofetilidum [INN-Latin]; Dofetilide; Tikosyn; UK68798; N-[4-[2-[Methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide; UK-68798; Dofetilide

登记号

• CAS号: 115256-11-6
• MDL号: MFCD00869707
• PubChem SID: 160963552; 46509127
• PubChem CID: 71329

理论计算性质

JChem

• Acid pKa: 10.145184
• 质子受体: 6
• 质子供体: 2
• LogD (pH = 5.5): -2.6246078
• LogD (pH = 7.4): -1.0490478
• Log P: 0.23791575
• 摩尔折射率: 113.2743 cm^3
• 极化性: 45.58207 Å^3
• 极化表面积: 104.81 Å^2
• 可自由旋转的化学键: 9
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 2.17
• LOG S: -4.35
• 溶解度: 1.98e-02 g/l

分子性质

理化性质

• 溶解度: DMSO: >20 mg/mL
• 外观: white to off-white powder
• 疏水性(logP): 2.1

安全信息

• 保存条件: -20°C
• 欧盟危险性物质标志: 环境危害性(Nature polluting) (N); 有毒(Toxic) (T)
• 德国WGK号: nwg
• 危险公开号: 61-48/22-51
• 安全公开号: 53-22-36-57
• GHS危险品标识: GHS07; GHS08
• GHS警示词: Danger
• GHS危险声明: H302-H360
• GHS警示性声明: P201-P308 + P313
• 保存温度: room temp

产品相关信息

• 纯度: ≥98% (HPLC)
• 成盐信息: Free Base
• Empirical Formula (Hill Notation): C19H27N3O5S2

详细说明

DrugBank - DB00204

• Drug Groups: approved
• Description: Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. [Wikipedia]
• Indication: For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
• Pharmacology: Dofetilide is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties and is indicated for the maintenance of normal sinus rhythm. Dofetilide increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. At concentrations covering several orders of magnitude, Dofetilide blocks only IKr with no relevant block of the other repolarizing potassium currents (e.g., IKs, IK1). At clinically relevant concentrations, Dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic
• Absorption: >90%
• Half Life: 10 hours
• Protein Binding: 60% -70%
• Distribution: * 3 L/kg
• References: Lenz TL, Hilleman DE: Dofetilide, a new class III antiarrhythmic agent. Pharmacotherapy. 2000 Jul;20(7):776-86. [Pubmed] ; Lenz TL, Hilleman DE: Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter. Drugs Today (Barc). 2000 Nov;36(11):759-71. [Pubmed] ; Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999 Sep 16;341(12):857-65. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

Selleck Chemicals - S1658

Research Area: Cardiovascular Disease
Biological Activity:
Dofetilide(Tikosyn) is a class III antiarrhythmic agent.The elimination half-life of dofetilide is roughly 10 hours, however this is variable based on many physiologic factors (most significantly creatinine clearance), and ranges from 4.8 to 13.5 hours. [1]

Sigma Aldrich - PZ0016

Biochem/physiol Actions
Dofetilide is a Class III antiarrhythmic and hERG channel blocker. Dofetilide selectively blocks the rapid component of the delayed rectifier outward potassium current (IKr).
Legal Information
Sold for research purposes under agreement from Pfizer Inc.

参考文献

• Lenz TL, Hilleman DE: Dofetilide, a new class III antiarrhythmic agent. Pharmacotherapy. 2000 Jul;20(7):776-86. Pubmed
• Lenz TL, Hilleman DE: Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter. Drugs Today (Barc). 2000 Nov;36(11):759-71. Pubmed
• Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999 Sep 16;341(12):857-65. Pubmed
• http://en.wikipedia.org/wiki/Dofetilide